Priming of PC12 cells for semiquantitative microinjection studies involving Ras  by Schmidt, Gudula & Wittinghofer, Alfred
Priming of PC12 cells for semiquantitative microinjection studies
involving Ras
Gudula Schmidt1, Alfred Wittinghofer*
Max-Planck-Institut fu«r molekulare Physiologie, Otto-Hahn-Str. 11, 44227 Dortmund, Germany
Received 21 March 2000; received in revised form 8 May 2000
Edited by Giulio Superti-Furga
Abstract Nerve growth factor and activated Ras can induce
differentiation of rat pheochromocytoma cells (PC12 cells)
[Greene and Tischler (1976) Proc. Natl. Acad. Sci. USA 73,
2424^2428] from a chromaffin cell-like morphology into one that
resembles sympathetic neurones. We developed a special
treatment of PC12 cells which apparently synchronises these
cells such that they are more useful for semi-quantitative
microinjection studies for signal transduction pathways. This
treatment leads to a faster and more reproducible differentiation
which faithfully reproduces the involvement of Ras in the process
and allows a comparison of the biological activity of different
Ras mutants. It shows that G12V and Q61L oncogenic mutants
are not equally potent in inducing differentiation. Partial loss-of-
function mutations T35S, E37G and Y40C are inactive and even
a triple combination of these does not restore full biological
activity.
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1. Introduction
Ras genes (H-, N-, K-Ras) are involved in many signal
transduction cascades, one of which is the activation of one
or more mitogen-activated protein kinase pathways [2^5].
Therefore the development of biological assays to analyse
the biological activity of wild-type and mutant Ras genes to
understand the function of these signal switch molecules has
been a major focus of recent research. Most of these assays
are based on the ability of Ras to induce mitogenesis and
focus formation in ¢broblasts. Genetic evidence from £ies
and worms has suggested that Ras is apparently equally im-
portant for di¡erentiation pathways. Genetic model systems
have been the development of photoreceptor cells during the
formation of the compound eye of Drosophila or the develop-
ment of a vulva from appropriate precursor cells in Caeno-
rhabditis elegans [6]. Ras has also been found to be involved in
the signal transduction from the di¡erentiation factor nerve
growth factor (NGF) in cultured neurones [7^9].
In the rat pheochromocytoma cell, PC12 [1], it has been
shown that transfection of Ras genes or microinjection of
Ras proteins into the cell leads to the development of neurites
[10^12]. While microinjection of proteins into mammalian
cells is a very direct way of assessing their biological potency,
its drawback is the usually long development of a cellular
response and the lack of reproducibility due to the lack of
synchronisation of biological material. Here we have devel-
oped a method for priming PC12 cells that allows an easy
assessment of biological activity of Ras proteins, and to com-
pare wild-type with di¡erent types of mutants.
2. Materials and methods
PC12 cells (clone 251-c/3, a subclone with high NGF responsive-
ness) were cultivated in 85% Dulbecco’s modi¢ed Eagle’s medium, (1
g/l glucose), 10% horse serum, 5% foetal bovine serum. 5U104 cells
were seeded per 25 cm2 Falcon tissue culture £ask in 5 ml medium
and maintained at 37‡C with 10% CO2. They were passaged every
week and split 1:6^1:8. For priming cells were singularised due to
trituration with a sterile tip and about 2U104 cells per Corning 35
mm tissue culture dish were plated in 2.5 ml culture medium. One
hundred ng/ml NGF was added per dish and the cells were incubated
for 3 days at 37‡C with 10% CO2. After that the cells were washed
three times with medium and further cultivated in 2.5 ml fresh me-
dium without NGF. Directly after retraction of the cells’ neurites
(usually after 2 days) the cells were microinjected.
Most of the Ras proteins used have been described before, and are
expressed and puri¢ed using the protocol described earlier [39]. Mi-
croinjections were performed on a Zeiss microinjection work station
with capillaries with a tip smaller than 0.25 Wm in diameter. Proteins
were diluted to 150 WM in phosphate-bu¡ered saline or standard
protein bu¡er (50 mM Tris^HCl, pH 7.6, 5 mM MgCl2 and 5 mM
dithiothreitol) and centrifuged for 2 min before injection. After injec-
tion 100 Wl penicillin/streptomycin solution was added to the medium.
After 24 h cells with neurites were counted. Between 100 and 200 cells
were injected per data point and each measurement was repeated at
least three (up to six) times. Microinjected cells are scored as those
being blown up during the procedure.
3. Results and discussion
Fig. 1 (¢rst columns) shows the results of microinjecting
wild-type Ras into PC12 cells. The number of positively
scored cells showing neurites (cells bearing neurites longer
than two times the cell diameter were scored as positive)
varies between 2 and 35% under apparently identical condi-
tions. This is probably due to the cells being in di¡erent stages
of the cell cycle at the time of microinjection. To obtain more
reproducible results and thus be able to use this di¡erentiation
assay to assess at least semi-quantitatively the biological ac-
tivity of Ras and its mutants, we tried to synchronise the cells
such that they responded more uniformly to the treatment.
It has been shown before that PC12 cells undergo a change
in their potential to grow out neurites in the presence of NGF
that has been termed ‘priming’ [13]. The priming method de-
scribed involves exposing cells for more than 10 days to NGF
and shearing o¡ their neurites. After introducing NGF the
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 6 0 2 - 1
*Corresponding author. Fax: (49)-231-1332199.
E-mail: alfred.wittinghofer@mpi-dortmund.mpg.de
1 Present address: Institut fu«r Pharmakologie und Toxikologie,
Albert-Ludwigs-University, Hermann-Herder-Str. 5, 79104 Freiburg
i.Br., Germany.
FEBS 23730 25-5-00
FEBS 23730FEBS Letters 474 (2000) 184^188
cells need just 1^2 days for the development of neurites. Un-
primed NGF-treated cells start neurite outgrowth after a lag
of about 24 h and require up to 7 days until most cells bear
neurites [14]. Primed cells are more responsive to NGF and
have been used to detect NGF in gold¢sh brain [15].
We have tested various preincubation methods which in-
volve pretreatment of cells with and subsequently without
NGF for di¡erent times as indicated in Fig. 1. Contrary to
the Green and Tischler method, we did not mechanically
shear o¡ the extensions, but allowed them to retract by them-
selves. The development of neurites after microinjection of
wild-type and mutant Ras highly depends on the culturing
conditions. By changing the time periods of stimulation and
cultivation with and without NGF it was possible to ¢nd the
optimal conditions for highly reproducible microinjection ex-
periments. It was also possible to adjust the level of the re-
sponse of PC12 cells to di¡erent levels as indicated (Fig. 1).
Since we wanted to compare Ras mutants with higher and
lower activity than wild-type, we chose conditions where
wild-type Ras induces 20% of the cells to induce neurite out-
growth after 24 h, where normal unprimed cells need more
than 48 h for full response, indicating that the lag phase has
been shortened. This is particular useful for microinjection
since we cannot expect all the Ras mutants to be equally
stable under the conditions of the experiment. The major ad-
vantage of our priming method as compared to that of Bur-
stein and Greene seems to be that it is more gentle on the
cells, as 90% of them survive injection. The method also ap-
pears to be much more reproducible and easy to perform. In
the following the protocol for microinjection always uses the
conditions of treatment of the cells for 3 days with and 2 days
without NGF. Because even NGF-untreated PC12 cells some-
times bear small extensions only cells with neurites longer
than two times the cell diameter were scored as positive.
3.1. Di¡erentiation is dependent on transcription
One property of cells primed according to Green and Tisch-
ler is their ability to grow out neurites in the presence of
transcription inhibitors such as actinomycin D, in contrast
to unprimed cells. Since our preconditioning involves treat-
ment with NGF for only 3 days we wondered whether neurite
induction in these cells requires transcription. Under the con-
ditions reported by Greene and Tischler (8 WM actinomycin
D), neurite outgrowth is completely inhibited in the condi-
tioned just as in non-conditioned cells, which means that the
process requires RNA synthesis.
Since actinomycin inhibits neurite outgrowth but a 24 h lag
phase is not observed under the conditions used in our assay,
Fig. 1. Priming of PC12 cells for microinjection. PC12 cells were stimulated ¢rst with, then without NGF before microinjection of wild-type
Ras protein, and are scored as % injected proteins showing neurites with twice the cell body length. The time of induction is indicated below
as x/y where x is the number of days the cells have been incubated with, y that without NGF. The experiment was repeated at least ¢ve times,
see parallel rows, to indicate the reproducibility.
Fig. 2. E¡ect of varying concentrations of actinomycin D in nM (as indicated) on neurite outgrowth of primed and unprimed PC12 cells. Col-
umns 1^3 are primed, columns 4^6 unprimed cells. Treatment of cells with NGF was for 24 (1,4), 48 (2,5) and 72 (3,6) h. With higher concen-
trations of actinomycin only primed cells (columns 1^3) were used.
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we assume that a su⁄cient set of proteins needed for the
initiation of the response does exist in the cells after priming,
but that some transcription is still necessary for prolonged
neurite outgrowth. To test this the inhibition experiment
was repeated with lower concentrations of actinomycin D,
such that RNA synthesis is only partially blocked (Fig. 2).
Even low concentrations of actinomycin D (0.002 WM) inhibit
neurite outgrowth, but the e¡ect on primed cells is much
weaker than on unprimed cells. In the presence of 4 nM acti-
nomycin D 40^50% of the primed cells are able to grow out
neurites during 24 h cultivation with NGF, whereas none of
the control cells bear neurites even after 3 days cultivation
with NGF.
3.2. Microinjection of Ras proteins
With a suitable assay to measure the biological activity of
Ras proteins at hand we tested a panel of mutants with var-
ious biochemical properties. Fig. 3 shows that the percentage
of neurite producing cells varies between 0 and 85% with
di¡erent mutants of Ras, and two representative examples
are documented in Fig. 4. The variation between di¡erent
experiments is minimal and the standard error normally
ranges from 0 to 4.6%. One can see that oncogenic mutants
such as Gly-12 (Fig. 4A) have the strongest biological e¡ect
comparable to that of NGF, whereas the Q61 mutants are less
e⁄cient in producing a biological readout. As a control, trun-
cated Ras(G12V), residues 1^166, shows no biological activity
con¢rming the necessity of the intact and fully modi¢ed C-
terminus for the biological activity [16^20]. The Q61E mu-
tants is likely inactive due to the instability of protein [21].
This is corroborated by the Q61E,E63Q double mutant, which
preserves the GTPase-negative mutation Q61E, but is stabi-
lised by the E63Q mutation, and is now a potent neurite
inducer. It has been shown that mutants with increased dis-
sociation rates for guanine nucleotides are also able to induce
transformation or PC12 di¡erentiation. Fig. 3 shows as an
example D119N, which is a transforming mutant that has a
low a⁄nity for guanine nucleotides [22^25] and has a similar
increase in its a⁄nity for xanthine nucleotides [24,25]. Its po-
tency is similar to that of oncogenic Gln61 mutants. The
totally conserved Ala-146, whose main-chain nitrogen inter-
acts with the O6 oxygen of the guanine base, is responsible for
the speci¢city of guanine binding. The A146P mutation has
very weak a⁄nity for guanine nucleotides (data not shown)
and correspondingly is a strong inducer of neurite outgrowth,
actually the most biologically potent protein tested by us.
Fig. 3. Biological activity of a panel of wild-type and mutant Ras proteins, as indicated below the columns, on neurite outgrowth of PC12 cells
primed by the standard procedure of incubating for 3 days with and 2 days without NGF. The number of columns for each mutant indicates
the number of independent experiments.
Fig. 4. Representative examples of the microinjection assay, showing
PC12 cells 2 days after microinjection of Ras(G12V) (A) and Y32R
(B).
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That the assay is very sensitive to small changes in biolog-
ical activity is shown by the G12P mutant which was reported
to be the only mutation of Gly-12 that is not oncogenic [26],
presumably because the intrinsic GTPase is 2^3-fold faster
than that of wild-type [27,28]. Since the GTPase activity of
p21(G12P) is not stimulated by GAP, it has been proposed
that the intrinsic activity is solely responsible for the biolog-
ical behaviour of p21 mutants [29]. Fig. 3 shows that
p21(G12P) is nevertheless twice as active as wild-type p21
and that the increased GTPase rate of the mutant cannot
totally compensate for the loss of GAP stimulation. Other
mutants with an e¡ect intermediate between wild-type and
oncogenic Ras are the loop L4 mutants such as E62H,
E63A, E63A, most likely due to the reduced interaction
with GAP as shown by the three-dimensional structure of
the complex [30]. Y32R (Fig. 4B), although only partially
reactive in the GAP-mediated GTPase reaction, is neverthe-
less not biologically active due to its inability to react with
e¡ectors (C. Herrmann, unpublished).
Recently it has become clear that Ras uses more than one
pathway to mediate the downstream response such as trans-
formation. Mutants of Ras in the e¡ector region have been
identi¢ed which are supposed to be speci¢cally blocked in a
particular pathway [31^38]. Such partial loss-of-function mu-
tants can be used to delineate the speci¢c downstream signal-
ling components of a particular pathway. It is generally be-
lieved that E37G, T35S and Y40C are speci¢c inducers of the
RalGEF, Raf and PI-3 kinase pathways, respectively. These
mutants, in the context of the GTPase-negative mutant G12V,
were thus tested in the context of the PC12 di¡erentiation
assay presented here. Fig. 5 shows that the single mutants
have drastically decreased di¡erentiation activity, which ac-
cording to common wisdom would mean that all three Ras
pathways mentioned are involved in the di¡erentiating activity
of the protein. It has been postulated that combining partial
losses-of-function restores biological activity. However, as
shown in Fig. 5, none of the double combinations of single
point mutations restores a large amount of biological activity,
and only the triple combination restores 50% activity. This
con¢rms our detailed biochemical analysis of Ras^e¡ector
interactions which show that all the commonly used partial
loss-of-function mutations have reduced a⁄nities to di¡erent
e¡ectors (data not shown), which would make it unlikely that
the combinations of the mutants would fully restore the path-
ways and thus biological function. As a caveat it should be
noted that the results obtained with the PC12 cell line cannot
necessarily be applied to a more physiological system such as
postmitotic neurones although Ras has been shown to be
responsible for survival and maintenance of di¡erentiation
of primary neurones as well [7,8].
Acknowledgements: We thank Doro Vogt for cloning and preparation
of Ras mutants, Brigitte Oeke for help in microinjection studies and
Rita Schebaum for secretarial assistance.
References
[1] Greene, L.A. and Tischler, A.S. (1976) Proc. Natl. Acad. Sci.
USA 73, 2424^2428.
[2] Camp¢eld, L.A., Smith, F.J. and Burn, P. (1998) Science 280,
1383^1387.
[3] Rubin, G.M., Chang, H.C., Karim, F., Laverty, T., Michaud,
N.R., Morrison, D.K., Rebay, I., Tang, A., Therrien, M. and
Wassarman, D.A. (1997) Cold Spring Harbor Symp. Quant.
Biol. 62, 347^352.
[4] Pronk, G.J. and Bos, J.L. (1994) Biochim. Biophys. Acta 1198,
131^147.
[5] Abrams, S.I., Hand, P.H., Tsang, K.Y. and Schlom, J. (1996)
Semin. Oncol. 23, 118^134.
[6] Sternberg, P.W. and Han, M. (1998) Trends Genet. 14, 466^472.
[7] Borasio, G.D., John, J., Wittinghofer, A., Barde, Y.A., Sendtner,
M. and Heumann, R. (1989) Neuron 2, 1087^1096.
[8] Borasio, G.D., Markus, W., Wittinghofer, A., Barde, Y.A. and
Heumann, R. (1993) J. Cell Biol. 121, 665^672.
[9] Heumann, R. (1994) Curr. Opin. Neurobiol. 4, 668^679.
[10] Noda, M., Ko, M., Ogura, A., Liu, D.-G., Amano, T., Takano,
T. and Ikawa, Y. (1985) Nature 318, 73^75.
[11] Bar-Sagi, D. and Feramisco, J.R. (1985) Cell 42, 841^848.
[12] Guerrero, I., Wong, H., Pellicer, A. and Burstein, D.W. (1986)
J. Cell Physiol. 129, 71^76.
[13] Burstein, D.E. and Greene, L.A. (1978) Proc. Natl. Acad. Sci.
USA 75, 6056^6063.
[14] Greene, L.A. and Tischler, A.S. (1982) Adv. Cell Neurobiol. 3,
373^415.
[15] Benowitz, L.I. and Greene, L.A. (1979) Brain Res. 162, 164^168.
[16] Willumsen, B.M., Christensen, A., Hubbert, N.L., Papageorge,
A.G. and Lowy, D.R. (1984) Nature 310, 583^586.
[17] Hancock, J.F., Magee, A.I., Childs, J.E. and Marshall, C.J.
(1989) Cell 57, 1167^1177.
[18] Gutierrez, L., Magee, A.I., Marshall, C.J. and Hancock, J.F.
(1989) EMBO J. 8, 1093^1098.
[19] Cox, A.D. and Der, C.J. (1997) Biochim. Biophys. Acta 1333,
F51^F71.
[20] John, J., Schlichting, I., Schiltz, E., Ro«sch, P. and Wittinghofer,
A. (1989) J. Biol. Chem. 264, 13086^13092.
[21] Frech, M., Darden, T.A., Pedersen, L.G., Foley, C.K., Charif-
son, P.S., Anderson, M.W. and Wittinghofer, A. (1994) Biochem-
istry 33, 3237^3244.
[22] Feig, L.A., Pan, B.-T., Roberts, T.M. and Cooper, G.M. (1986)
Proc. Natl. Acad. Sci. USA 83, 4607^4611.
[23] Der, C.J., Weissmann, B. and MacDonald, M.J. (1988) Onco-
gene 3, 105^112.
[24] Schmidt, G., Lenzen, C., Simon, I., Deuter, R., Cool, R.H.,
Goody, R.S. and Wittinghofer, A. (1996) Curr. Biol. 4, 547^550.
[25] Zhong, J.-M., Chen-Hwang, M.-C. and Hwang, Y.-W. (1995)
J. Biol. Chem. 270, 10002^10007.
[26] Seeburg, P.H., Colby, W.W., Capon, D.J., Goedel, D.V. and
Levinson, A.D. (1984) Nature 312, 71^75.
[27] Gibbs, J.B., Schaber, M.D., Allard, W.J., Sigal, I.S. and Scol-
nick, E.M. (1988) Proc. Natl. Acad. Sci. USA 85, 5026^5030.
[28] Schweins, T., Geyer, M., Sche¡zek, K., Warshel, A., Kalbitzer,
H.R. and Wittinghofer, A. (1995) Nature Struct. Biol. 2, 36^44.
Fig. 5. E¡ect of single or combinations of partial loss-of-function
mutations on neurite outgrowth of primed PC12 cells, relative to
the e¡ect of the oncogenic Ras(G12V) mutant, which is 100%.
FEBS 23730 25-5-00
G. Schmidt, A. Wittinghofer/FEBS Letters 474 (2000) 184^188 187
[29] Eccleston, J.F., Moore, K.J.M., Morgan, L., Skinner, R.H. and
Lowe, P.N. (1993) J. Biol. Chem. 268, 27012^27019.
[30] Sche¡zek, K., Ahmadian, M.R., Kabsch, W., Wiesmu«ller, L.,
Lautwein, A., Schmitz, F. and Wittinghofer, A. (1997) Science
277, 333^338.
[31] White, M.A., Nicolette, C., Minden, A., Polverino, A., Van
Aelst, L., Karin, M. and Wigler, M.H. (1995) Cell 80, 1^20.
[32] Akasaka, K., Tamada, M., Wang, F., Kariya, K.-i., Shima, F.,
Kikuchi, A., Yamamoto, M., Shirouzu, M., Yokoyama, S. and
Kataoka, T. (1996) J. Biol. Chem. 271, 5353^5360.
[33] Rodriguez-Viciana, P., Warne, P.H., Vanhaesebroeck, B., Water-
¢eld, M.D. and Downward, J. (1996) EMBO J. 15, 2442^2451.
[34] Rodriguez-Viciana, P., Warne, P.H., Khwaja, A., Marte,
B.M.N., Pappin, D., Das, P., Water¢eld, M.D., Ridley, A. and
Downward, J. (1997) Cell 89, 457^467.
[35] Khosravi-Far, R., White, M.A., Westwick, J.K., Solski, P.A.,
Chrzanowska-Wodnicka, M., van Aelst, L., Wigler, M.H. and
Der, C.J. (1996) Mol. Cell. Biol. 16, 3923^3933.
[36] White, M.A., Vale, T., Camonis, J.H., Schaefer, E. and Wigler,
M.H. (1996) J. Biol. Chem. 271, 16439^16442.
[37] Joneson, T., White, M.A., Wigler, M.H. and Bar-Sagi, D. (1996)
Science 271, 810^812.
[38] Wolthuis, R.M.F., Deruiter, N.D., Cool, R.H. and Bos, J.L.
(1997) EMBO J. 16, 6748^6761.
[39] John, J., Frech, M. and Wittinghofer, A. (1988) J. Biol. Chem.
263, 11792^11799.
FEBS 23730 25-5-00
G. Schmidt, A. Wittinghofer/FEBS Letters 474 (2000) 184^188188
